ClinicalTrials.gg
CompletedNCT02581995AQUAUpdated Oct 10, 2018Results posted

Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.

A Phase 4 interventional study of Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321) in Macular Edema, sponsored by Bayer. Completed at 76 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-10.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
560
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.

Enrollment
3rd of 53
560 · median 49
Started
2015
with 10 others
Phase 4
26 of 53
none open now
Registered
22nd of 53
by date
Lead sponsor
9 of 53
Bayer

Among the 53 studies testing aflibercept in Macular Edema, this one is the 3rd largest by enrollment, is one of 11 that started in 2015, is one of 26 in phase 4, and was the 22nd registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing aflibercept in Macular Edema, or all of them as a file.
02

Study summary

To evaluate the change in quality of life (NEI VFQ 25) in subjects with DME during the first year of treatment with aflibercept according to the EU Label.

03

Conditions studied

  • Macular Edema

Browse trials for

Keywords

  • Diabetic macular edema
  • Intravitreal injection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 or 2 diabetes mellitus
  • Diagnosis of DME secondary to diabetes mellitus involving the center of the macula (defined as the area of the center subfield on OCT) in the study eye
  • Decrease in vision determined to be primarily the result of DME in the study eye
  • BCVA in the study eye of ETDRS letter score 73 to 24 (This corresponds to a Snellen equivalent of approximately 20/40 to 20/320.)

Exclusion criteria

Exclusion Criteria:

  • Pregnancy and lactation
  • Mismatch with inclusion criteria
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
560 participants (actual)

Study arms

  • Experimental
    Arm 1 / Quality of Life

    Aflibercept treatment in subjects with diabetic macular edema (DME)

    Drug: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 52 in NEI VFQ-25 Total Score

    National eye institute 25-item visual function questionnaire (NEI VFQ-25) is a condition-specific measure which was designed to capture the specific impact of vision loss on health-related quality of life (HRQoL). The calculation for NEI VFQ-25 sub-scale scores and total score was performed according to the "NEI VFQ-25 Scoring Algorithm - August 2000". The NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. In this format scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score.

    Time frame: Baseline, Week 52

Secondary outcomes

  1. Change From Baseline to Week 52 in the NEI VFQ 25 Near Activities Subscale

    NEI VFQ-25 is a condition-specific measure which was designed to capture the specific impact of vision loss on HRQoL. The calculation for NEI VFQ-25 sub-scale scores and total score was performed according to the "NEI VFQ-25 Scoring Algorithm - August 2000". Items within each sub-scale are averaged together to create the 12 sub-scale Scores. Items that are left blank (missing data) are not taken into account when calculating the scale scores. Sub-scales with at least one item answered can be used to generate a sub-scale score. Hence, scores represent the average for all items in the subscale that the respondent answered.The NEI VFQ-25 near activities subscale was scored from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.

    Time frame: Baseline, Week 52

  2. Change From Baseline to Week 52 in the NEI VFQ 25 Distant Activities Subscale

    NEI VFQ-25 is a condition-specific measure which was designed to capture the specific impact of vision loss on HRQoL. The calculation for NEI VFQ-25 sub-scale scores and total score was performed according to the "NEI VFQ-25 Scoring Algorithm - August 2000". Items within each sub-scale are averaged together to create the 12 sub-scale Scores. Items that are left blank (missing data) are not taken into account when calculating the scale scores. Sub-scales with at least one item answered can be used to generate a sub-scale score. Hence, scores represent the average for all items in the subscale that the respondent answered. The NEI VFQ-25 distant activities subscale was scored from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. Distant activities are defined as activities requiring distance vision, such as recognizing faces or reading street signs.

    Time frame: Baseline, Week 52

  3. Change From Baseline to Week 52 in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score])

    Visual function was assessed using the ETDRS protocol (Early Treatment Diabetic Retinopathy Study Research Group 1985) starting at 4 meters. The values might range from 0 to 100. A higher score represents better functioning.

    Time frame: Baseline, Week 52

  4. Change From Baseline to Week 52 in Central Retinal Thickness (CRT) Measured by Optical Coherence Tomography (OCT)

    Retinal and lesion characteristics were evaluated using spectral domain optical coherence tomography (OCT). For all visits where the OCT procedure was scheduled, images were captured and read by the investigator. All OCTs were electronically archived at the study sites as part of the source documentation.

    Time frame: Baseline, Week 52

  5. Proportion of Participants Progressing to Greater or Equal to (>=) 61 on the ETDRS Diabetic Retinopathy Severity Scale (DRSS) as Assessed by Fundus Photography (FP)

    The ETDRS DRSS was assessed by FP according to the following scale for both eyes. The following severities are possible. 10 = Diabetic retinopathy (DR) absent, 14 = DR questionable, 15 = DR questionable, 20 = Micro-aneurysms only, 35 = Mild Non-proliferative diabetic retinopathy (NPDR), 43 = Moderate NPDR, 47 = Moderately severe NPDR, 53 = Severe NPDR, 61 = Mild Proliferative diabetic retinopathy (PDR), 65 = Moderate PDR, 71 = High-risk PDR, 75 = High-risk PDR, 81 = Advanced PDR: fundus partially obscured, center of macula attached, 85 = Advanced PDR: posterior fundus obscured, or center of macula detached, 90 = cannot grade, even sufficiently for level 81 or 85.

    Time frame: Baseline, Week 52

Other outcomes

  1. Change From Baseline in Pre-injection Intraocular Pressure for Study Eye Every 4 Weeks

    Intraocular pressure (IOP) was measured using applanation tonometry Goldmann, Tonopen or approved alternative). The same method of intraocular pressure measurement was used in each participant throughout the study. For the measurement of intraocular pressure, a local anesthetic combined with fluorescein was applied topically to the eye being tested (example: one drop of oxybuprocain plus fluorescein). In the below table, pre-injection intraocular pressure for study eye was reported.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 24, 32, 40, 48, 52

  2. Change From Baseline in Systolic Blood Pressure at Week 52

    Systolic blood pressure was measured in a consistent and standardized way according to locally established practice.

    Time frame: Baseline, Week 52

  3. Change From Baseline in Diastolic Blood Pressure at Week 52

    Diastolic blood pressure was measured in a consistent and standardized way according to locally established practice.

    Time frame: Baseline, Week 52

  4. Change From Baseline in Heart Rate at Week 52

    Heart rate was measured in a consistent and standardized way according to locally established practice.

    Time frame: Baseline, Week 52

  5. Change From Baseline in Body Temperature at Week 52

    Temperature was measured in a consistent and standardized way according to locally established practice.

    Time frame: Baseline, Week 52

07

Results

Posted Oct 10, 2018

Participant flow

Study was conducted at multiple study centers in 14 countries, between 19 November 2015 (first participant first visit) and 09 August 2017 (last participant last visit).

Participant flow — Overall Study
MilestoneAflibercept
Started560
Treated560
Completed529
Not completed31
Withdrew: Unspecified other3
Withdrew: Adverse event6
Withdrew: Lost to follow-up5
Withdrew: Withdrawal by participant12
Withdrew: Physician decision1
Withdrew: Death4

Outcome measures

PrimaryChange From Baseline to Week 52 in NEI VFQ-25 Total Score

National eye institute 25-item visual function questionnaire (NEI VFQ-25) is a condition-specific measure which was designed to capture the specific impact of vision loss on health-related quality of life (HRQoL). The calculation for NEI VFQ-25 sub-scale scores and total score was performed according to the "NEI VFQ-25 Scoring Algorithm - August 2000". The NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. In this format scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score.

Time frame:
Baseline, Week 52
Reported as:
Mean · score on a scale
Change From Baseline to Week 52 in NEI VFQ-25 Total Score
score on a scaleAflibercept
Change From Baseline to Week 52 in NEI VFQ-25 Total Score6.106 (5.303 to 6.909)
SecondaryChange From Baseline to Week 52 in the NEI VFQ 25 Near Activities Subscale

NEI VFQ-25 is a condition-specific measure which was designed to capture the specific impact of vision loss on HRQoL. The calculation for NEI VFQ-25 sub-scale scores and total score was performed according to the "NEI VFQ-25 Scoring Algorithm - August 2000". Items within each sub-scale are averaged together to create the 12 sub-scale Scores. Items that are left blank (missing data) are not taken into account when calculating the scale scores. Sub-scales with at least one item answered can be used to generate a sub-scale score. Hence, scores represent the average for all items in the subscale that the respondent answered.The NEI VFQ-25 near activities subscale was scored from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.

Time frame:
Baseline, Week 52
Reported as:
Mean · score on a scale
Change From Baseline to Week 52 in the NEI VFQ 25 Near Activities Subscale
score on a scaleAflibercept
Change From Baseline to Week 52 in the NEI VFQ 25 Near Activities Subscale11.370 (10.108 to 12.632)
SecondaryChange From Baseline to Week 52 in the NEI VFQ 25 Distant Activities Subscale

NEI VFQ-25 is a condition-specific measure which was designed to capture the specific impact of vision loss on HRQoL. The calculation for NEI VFQ-25 sub-scale scores and total score was performed according to the "NEI VFQ-25 Scoring Algorithm - August 2000". Items within each sub-scale are averaged together to create the 12 sub-scale Scores. Items that are left blank (missing data) are not taken into account when calculating the scale scores. Sub-scales with at least one item answered can be used to generate a sub-scale score. Hence, scores represent the average for all items in the subscale that the respondent answered. The NEI VFQ-25 distant activities subscale was scored from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. Distant activities are defined as activities requiring distance vision, such as recognizing faces or reading street signs.

Time frame:
Baseline, Week 52
Reported as:
Mean · score on a scale
Change From Baseline to Week 52 in the NEI VFQ 25 Distant Activities Subscale
score on a scaleAflibercept
Change From Baseline to Week 52 in the NEI VFQ 25 Distant Activities Subscale7.331 (6.118 to 8.545)
SecondaryChange From Baseline to Week 52 in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score])

Visual function was assessed using the ETDRS protocol (Early Treatment Diabetic Retinopathy Study Research Group 1985) starting at 4 meters. The values might range from 0 to 100. A higher score represents better functioning.

Time frame:
Baseline, Week 52
Reported as:
Mean · score on a scale
Change From Baseline to Week 52 in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score])
score on a scaleAflibercept
Change From Baseline to Week 52 in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score])10.0 (9.5 to 10.6)
SecondaryChange From Baseline to Week 52 in Central Retinal Thickness (CRT) Measured by Optical Coherence Tomography (OCT)

Retinal and lesion characteristics were evaluated using spectral domain optical coherence tomography (OCT). For all visits where the OCT procedure was scheduled, images were captured and read by the investigator. All OCTs were electronically archived at the study sites as part of the source documentation.

Time frame:
Baseline, Week 52
Reported as:
Mean · microns
Change From Baseline to Week 52 in Central Retinal Thickness (CRT) Measured by Optical Coherence Tomography (OCT)
micronsAflibercept
Change From Baseline to Week 52 in Central Retinal Thickness (CRT) Measured by Optical Coherence Tomography (OCT)-175.38 (-184.93 to -165.82)
SecondaryProportion of Participants Progressing to Greater or Equal to (>=) 61 on the ETDRS Diabetic Retinopathy Severity Scale (DRSS) as Assessed by Fundus Photography (FP)

The ETDRS DRSS was assessed by FP according to the following scale for both eyes. The following severities are possible. 10 = Diabetic retinopathy (DR) absent, 14 = DR questionable, 15 = DR questionable, 20 = Micro-aneurysms only, 35 = Mild Non-proliferative diabetic retinopathy (NPDR), 43 = Moderate NPDR, 47 = Moderately severe NPDR, 53 = Severe NPDR, 61 = Mild Proliferative diabetic retinopathy (PDR), 65 = Moderate PDR, 71 = High-risk PDR, 75 = High-risk PDR, 81 = Advanced PDR: fundus partially obscured, center of macula attached, 85 = Advanced PDR: posterior fundus obscured, or center of macula detached, 90 = cannot grade, even sufficiently for level 81 or 85.

Time frame:
Baseline, Week 52
Reported as:
Number · proportion of participants
Proportion of Participants Progressing to Greater or Equal to (>=) 61 on the ETDRS Diabetic Retinopathy Severity Scale (DRSS) as Assessed by Fundus Photography (FP)
proportion of participantsAflibercept
Proportion of Participants Progressing to Greater or Equal to (>=) 61 on the ETDRS Diabetic Retinopathy Severity Scale (DRSS) as Assessed by Fundus Photography (FP)0.4
Other pre-specifiedChange From Baseline in Pre-injection Intraocular Pressure for Study Eye Every 4 Weeks

Intraocular pressure (IOP) was measured using applanation tonometry Goldmann, Tonopen or approved alternative). The same method of intraocular pressure measurement was used in each participant throughout the study. For the measurement of intraocular pressure, a local anesthetic combined with fluorescein was applied topically to the eye being tested (example: one drop of oxybuprocain plus fluorescein). In the below table, pre-injection intraocular pressure for study eye was reported.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 24, 32, 40, 48, 52
Reported as:
Mean · millimeter of mercury (mmHg)
Change From Baseline in Pre-injection Intraocular Pressure for Study Eye Every 4 Weeks
millimeter of mercury (mmHg)Aflibercept
Change at Week 4-0.4 ± 2.9
Change at Week 8-0.3 ± 2.9
Change at Week 12-0.5 ± 2.9
Change at Week 16-0.3 ± 2.9
Change at Week 24-0.2 ± 3.0
Change at Week 32-0.1 ± 3.0
Change at Week 400.0 ± 3.0
Change at Week 480.0 ± 3.0
Change at Week 520.1 ± 3.1
Other pre-specifiedChange From Baseline in Systolic Blood Pressure at Week 52

Systolic blood pressure was measured in a consistent and standardized way according to locally established practice.

Time frame:
Baseline, Week 52
Reported as:
Mean · millimeter of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure at Week 52
millimeter of mercury (mmHg)Aflibercept
Change From Baseline in Systolic Blood Pressure at Week 52-0.1 ± 15.1
Other pre-specifiedChange From Baseline in Diastolic Blood Pressure at Week 52

Diastolic blood pressure was measured in a consistent and standardized way according to locally established practice.

Time frame:
Baseline, Week 52
Reported as:
Mean · millimeter of mercury (mmHg)
Change From Baseline in Diastolic Blood Pressure at Week 52
millimeter of mercury (mmHg)Aflibercept
Change From Baseline in Diastolic Blood Pressure at Week 52-0.3 ± 9.9
Other pre-specifiedChange From Baseline in Heart Rate at Week 52

Heart rate was measured in a consistent and standardized way according to locally established practice.

Time frame:
Baseline, Week 52
Reported as:
Mean · beats per minute (beats/min)
Change From Baseline in Heart Rate at Week 52
beats per minute (beats/min)Aflibercept
Change From Baseline in Heart Rate at Week 52-1.0 ± 9.5
Other pre-specifiedChange From Baseline in Body Temperature at Week 52

Temperature was measured in a consistent and standardized way according to locally established practice.

Time frame:
Baseline, Week 52
Reported as:
Mean · celsius
Change From Baseline in Body Temperature at Week 52
celsiusAflibercept
Change From Baseline in Body Temperature at Week 52-0.04 ± 0.41

Adverse events

Collected over From start of study treatment up to 30 days after the last injection of study treatment, up to week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aflibercept5/560 (0.9%)66/560 (11.8%)0/560 (0%)
Most frequent serious events
Showing 10 of 70
Most frequent serious events
EventAflibercept
PneumoniaInfections and infestations6/560
EndophthalmitisInfections and infestations3/560
Cerebrovascular accidentNervous system disorders3/560
Cardiac failure acuteCardiac disorders2/560
Myocardial infarctionCardiac disorders2/560
Posterior capsule opacificationEye disorders2/560
VitritisEye disorders2/560
CellulitisInfections and infestations2/560
Diabetic foot infectionInfections and infestations2/560
Rib fractureInjury, poisoning and procedural complications2/560

Baseline characteristics

Safety analysis set (SAF) included all participants who received at least 1 injection of study drug.

Age, Continuous
Age, Continuous(years)Aflibercept
Mean64.3 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Aflibercept
Female224
Male336
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Aflibercept
American Indian or Alaska Native0
Asian4
Native Hawaiian or Other Pacific Islander0
Black or African American3
White519
More than one race0
Unknown or Not Reported34
Central Retinal Thickness (CRT)
Central Retinal Thickness (CRT)(microns)Aflibercept
Mean465.08 ± 136.75
Best Corrected Visual Acuity (BCVA)
Best Corrected Visual Acuity (BCVA)(score on a scale)Aflibercept
Mean61.5 ± 11.0
NEI VFQ-25 total score
NEI VFQ-25 total score(score on a scale)Aflibercept
Mean70.224 ± 19.221
NEI VFQ-25 near activities subscale
NEI VFQ-25 near activities subscale(score on a scale)Aflibercept
Mean62.967 ± 23.479
NEI VFQ-25 distant activities subscale
NEI VFQ-25 distant activities subscale(score on a scale)Aflibercept
Mean71.964 ± 23.973

6 further baseline measures are reported on the registry.

08

Study locations

76 sites
  • Graz, Steiermark 8036, Austria
  • Wien, 1090, Austria
  • Wien, 1140, Austria
  • Halifax, Nova Scotia B3H 2Y9, Canada
  • London, Ontario N6A 4V2, Canada
  • Mississauga, Ontario L4W 1W9, Canada
  • Ottawa, Ontario K1H 8L6, Canada
  • Toronto, Ontario M3C 0G9, Canada
  • Montreal, Quebec H4P 2S4, Canada
  • Sherbrooke, Quebec J1G 2V4, Canada
  • Hradec Kralove, 500 05, Czechia
  • Praha 10, 100 34, Czechia
  • Usti nad Labem, 401 13, Czechia
  • Creteil Cedex, 94010, France
  • Marseille, 13285, France
  • Darmstadt, Hessen 64276, Germany
  • Frankfurt, Hessen 60596, Germany
  • Marburg, Hessen 35043, Germany
  • Göttingen, Niedersachsen 37099, Germany
  • Bonn, Nordrhein-Westfalen 53105, Germany
  • Köln, Nordrhein-Westfalen 50937, Germany
  • Ludwigshafen, Rheinland-Pfalz 67063, Germany
  • Mainz, Rheinland-Pfalz 55131, Germany
  • Dresden, Sachsen 01067, Germany
  • Dresden, Sachsen 01307, Germany
  • Leipzig, Sachsen 04103, Germany
  • Budapest, 1083, Hungary
  • Budapest, 1106, Hungary
  • Budapest, 1133, Hungary
  • Debrecen, 4032, Hungary
  • Pecs, 7621, Hungary
  • Roma, Lazio 00133, Italy
  • Genova, Liguria 16132, Italy
  • Milano, Lombardia 20122, Italy
  • Milano, Lombardia 20132, Italy
  • Torino, Piemonte 10122, Italy
  • Cagliari, Sardegna 09124, Italy
  • Sassari, Sardegna 07100, Italy
  • Firenze, Toscana 50134, Italy
  • Padova, Veneto 35128, Italy
  • Kaunas, LT-50009, Lithuania
  • Vilnius, LT-08661, Lithuania
  • Bydgoszcz, 85-631, Poland
  • Gdansk, 80-809, Poland
  • Katowice, 40-594, Poland
  • Krakow, 31-501, Poland
  • Lodz, 91-134, Poland
  • Lublin, 20-079, Poland
  • Poznan, 61-285, Poland
  • Warszawa, 01-013, Poland
  • Warszawa, 04-141, Poland
  • Coimbra, 3000-548, Portugal
  • Leiria, 2410-197, Portugal
  • Lisboa, 1649-035, Portugal
  • Porto, 4200-319, Portugal
  • Vila Franca de Xira, 2600-178, Portugal
  • Bratislava, 826 06, Slovakia
  • Bratislava, 85107, Slovakia
  • Nitra, 949 01, Slovakia
  • Zilina, 01207, Slovakia
  • Zvolen, 960 01, Slovakia
  • L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • San Cugat Del Vallès, Barcelona 08190, Spain
  • Albacete, 02006, Spain
  • Barcelona, 08035, Spain
  • Barcelona, 08036, Spain
  • Valencia, 46014, Spain
  • Bern, Switzerland
  • Genève, 1204, Switzerland
  • Southampton, Hampshire SO16 6YD, United Kingdom
  • Camberley, Surrey GU16 7UJ, United Kingdom
  • Guildford, Surrey GU2 7XX, United Kingdom
  • Newcastle Upon Tyne, Tyne And Wear NE1 4LP, United Kingdom
  • Sunderland, Tyne And Wear SR2 9HP, United Kingdom
  • Leeds, West Yorkshire LS9 7TF, United Kingdom
  • London, EC1V 2PD, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Aug 2017, 20 months.

Results were first posted in Oct 2018, 1 year 2 months after primary completion.

Of 63 phase 4 interventional studies under Macular Edema, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 43. This study's 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2015
First posted
Oct 21, 2015
StartActual
Nov 19, 2015
Primary completionActual
Aug 9, 2017
CompletionActual
Aug 9, 2017
Results first posted
Oct 10, 2018
Last update
Oct 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02581995
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Oct 21, 2015
Start date
Nov 19, 2015
Primary completion
Aug 9, 2017
Completion
Aug 9, 2017
Results posted
Oct 10, 2018
Last update
Oct 10, 2018

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion